Disease-Modifying Therapy and Cognition in Patients With Multiple Sclerosis
August 29th 2022Ahmed Obeidat, MD, PhD; Randall Schapiro, MD, FAAN; and Jeffrey Wilken, PhD, share their opinions on the utility of disease-modifying therapies to increase cognition and brain health in patients with multiple sclerosis.
The Role of Preeclampsia and Inflammation in Late-Life Cognition: Vesna Garovic, MD, PhD
August 29th 2022The chair of the nephrology division at Mayo Clinic provided context on recent findings linking inflammation and neurovascular damage in women with a history of severe preeclampsia, and how the community may react. [WATCH TIME: 2 minutes]
Institutional Perspectives in Neurology, Chaired by Augusto Miravalle, MD
August 29th 2022Chaired by Augusto Miravalle, MD, of the University of Colorado, the presentations also feature Barry Hendin, MD, of the Center for Neurology and Spine; Ilana B. Katz Sand, MD, of Mount Sinai; Brett Fling, PhD, of Colorado State University; and Gavin Giovannoni, MBBCh, PhD, of Queen Mary University of London. [WATCH TIME: 1 hour, 59 minutes]
Expanding on the Cognitive Stress Test and Answering Cognitive Deficit Questions: Rosie Curiel, PsyD
August 25th 2022The associate professor of neuropsychology at the University of Miami Miller School of Medicine discussed the next steps in using the Cognitive Stress Test and the remaining questions from recent findings. [WATCH TIME: 4 minutes]
Future Research and Questions Surrounding GFAP, sTREM2 in Alzheimer Disease: Lynn Bekris, PhD
August 24th 2022The molecular biologist at the Cleveland Clinic Lerner Research Institute provided insight on the lingering questions about GFAP and sTREM2 astrocytes, and their immunologic correlations with Alzheimer disease and related dementias. [WATCH TIME: 4 minutes]
Long- and Short-Term Consequences of Pediatric Sleep Disorders: Jodi A. Mindell, PhD
August 23rd 2022The associate director of the Sleep Center at Children’s Hospital of Philadelphia discussed the detrimental effects poor sleep can have on children, both neurologically and on quality of life. [WATCH TIME: 4 minutes]
The Impact of Polypharmacy on Cognitive Health in MS
August 22nd 2022Ahmed Obeidat, MD, PhD; Randall Schapiro, MD, FAAN; and Jeffrey Wilken, PhD, discuss the impact of polypharmacy on cognitive health and share their thoughts on deciding when to cease treatments in patients with multiple sclerosis.
Exercise, Virtual Reality, and Exposing Prodromal Symptoms of Parkinson Disease: Jay Alberts, PhD
August 22nd 2022The Edward F. and Barbara A. Bell Endowed Chair at the Cleveland Clinic detailed how a new virtual reality tool elucidates prodromal symptoms from patients with Parkinson disease. [WATCH TIME: 3 minutes]
The Realities of Gender-Targeted Therapeutics for Alzheimer Disease: Jessica Caldwell, PhD
August 21st 2022The director of the Women’s Alzheimer’s Movement Preventer Center at Cleveland Clinic provided perspective on the possibility of gender-specific therapies to overcome disparities in Alzheimer disease. [WATCH TIME: 3 minutes]
Lessons About Alzheimer Disease and Related Dementias From GFAP, sTREM2 Astrocytes: Lynn Bekris, PhD
August 18th 2022The molecular biologist at the Cleveland Clinic Lerner Research Institute discussed research on the use of GFAP and sTREM2 in discerning dementia with Lewy bodies from Alzheimer disease. [WATCH TIME: 4 minutes]
Overcoming the Complexities With Gene Therapy in ALS: Anna Underhill, BS
August 18th 2022The postdoctoral researcher at King’s College London provided background on why gene therapies have not seen as much success in treating ALS, and the need for additional validation of genetic mutations. [WATCH TIME: 3 minutes]
Differences in the Genetic Mutations of ALS: Anna Underhill, BS
August 17th 2022The postdoctoral researcher at King’s College London provided insight on the immunologic differences between genes linked with ALS, and the important aspects to consider for gene-targeted therapies. [WATCH TIME: 3 minutes]